Friedlander M, Meniawy T, Markman B, et al. - In this trial conducted at five academic sites or community oncology centers in Australia, researchers focused on the combination of pamiparib {an oral poly [ADP-ribose] polymerase 1/2 inhibitor) and tislelizumab (a humanized anti-PD-1 monoclonal antibody) with respect to safety and antitumor impacts in patients with advanced solid tumors. They also intended to find out the optimum doses for further assessment. They 49 enrolled patients into one of five dose-escalation cohorts and used a 3 + 3 design for performing dose-escalation. They administered intravenous tislelizumab 2 mg/kg every 3 weeks plus 20, 40, or 60 mg oral pamiparib twice daily in cohorts 1–3, respectively. They administered 200 mg intravenous tislelizumab every 3 weeks plus 40 or 60 mg oral pamiparib twice daily in cohorts 4 and 5, respectively. Findings revealed general good tolerability of pamiparib with tislelizumab, as well as antitumor responses and clinical benefit in relation to this combination therapy in patients with advanced solid tumors.